Bristol-Myers Squibb Company
Bristol-Myers Squibb Company develops and sells biopharmaceutical products worldwide. Products treat diseases such as hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience conditions. Notable products include Eliquis, Opdivo, Pomalyst/Imnovid, Orencia, Sprycel, Yervoy, Empliciti, Abecma, Reblozyl, and more. The company offers various treatments for cancer, multiple myeloma, rheumatoid arthritis, psoriatic arthritis, melanoma, and more. Products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Overview
Strengths
- Shows the financial signature of a durable competitive advantage (economic moat): consistently high returns on capital, returns well above its cost of capital and an asset-light, cash-generative model.
- Return on invested capital has stayed above 15% in 6 of the last 7 years (latest 22.3%), a hallmark of a durable competitive advantage.
- Creates economic value: ROIC of 22.3% against a cost of capital (WACC) of 5.8%, a spread of 16.5 percentage points.
- Asset-light, cash-generative model: capital expenditure takes only 2.5% of revenue and free cash flow was positive in each of the last 7 years.
- Valued below its Drug Manufacturers - General peers: P/FCF 9.8x vs. a median of 21.6x and EV/EBITDA 8.1x vs. a median of 13.9x.
- Improving fundamentals over the last year: return on assets up 17.5 points and asset turnover up 2.6%.
Weaknesses
- Earnings are projected to decline (-10.0% per year).
Key Financial Data